Loading...
Loading...
ENSC| Name | Value |
|---|---|
| Revenues | 515.0K |
| Cost of Revenue | 3,439.7K |
| Gross Profit | -2,924.7K |
| Operating Expense | 3,670.7K |
| Operating I/L | -3,155.7K |
| Other Income/Expense | -348.7K |
| Interest Income | 0.0K |
| Pretax | -3,504.4K |
| Income Tax Expense | 360.5K |
| Net Income/Loss | -3,504.3K |
Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical company focused on developing abuse-resistant opioid prodrugs for severe pain relief and overdose protection. The company's products include PF614, a TAAP prodrug candidate of oxycodone for acute and chronic pain treatment; PF614-MPAR, a combination product for overdose protection; PF329, an extended-release prodrug of hydromorphone; PF8001 and PF8026, extended and immediate-release prodrugs of amphetamine for ADHD medication abuse; and PF26810, an extended-release prodrug of methadone for opioid use disorder.
